PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 503/18, A61K 31/42 | A2

(11) International Publication Number: WO 96/20199

(43) International Publication Date: 4 July 1996 (04.07.96)

(21) International Application Number: PCT/GB95/03039

(22) International Filing Date: 22 December 1995 (22.12.95)

(30) Priority Data:
9426261.5 24 December 1994 (24.12.94) GB

(71) Applicant *(for all designated States except US)*: SPURCOURT LIMITED [GB/GB]; The Pollock Building, Ladbroke Close, Woodley, Reading RG5 4DX (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: CALLWAERT, George, Leo [GB/GB]; Meadows End, Beacon Hill, Penn, Buckingham HP10 8NH (GB).

(74) Agent: AUSTIN, Hedley, William; Urquhart-Dykes & Lord, Alexandra House, Alexandra Road, Swansea SA1 5ED (GB).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).

Published

Without international search report and to be republished upon receipt of that report.

RTMP copy

(54) Title: CLAVULANIC ACID SALTS

(57) Abstract

A di-clavulanate salt derived from clavulanic acid and a diamino ether of formula (I), where R^1 is an alkylene group, optionally having one or more inert substituents; and each of R^2 and R^3 is a hydrogen atom or an alkyl group, optionally having one or more inert substituents, or R^2 and R^3 together complete a heterocyclic ring having 4 to 7 carbon atoms, again optionally having one or more inert substituents. The salt is prepared by reacting a bis(2-dialkylaminoalkylene)ether (or a salt thereof) with clavulanic acid in an organic solvent and isolating the resulting salt. The clavulanic acid salt can be used in pharmaceutical formulations together with a pharmaceutically acceptable carrier, and, optionally, a beta-lactam antibiotic, and is useful as an intermediate for the potassium salt.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

9702992-0